Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
5.31
+0.11 (2.12%)
At close: Mar 6, 2026, 4:00 PM EST
5.29
-0.02 (-0.38%)
After-hours: Mar 6, 2026, 4:10 PM EST
Verrica Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 30.83 | 7.57 | 5.12 | 9.03 | 12 | - | Upgrade
|
| Revenue Growth (YoY) | 234.73% | 47.66% | -43.27% | -24.73% | - | - | Upgrade
|
| Cost of Revenue | 10.17 | 14.58 | 21.04 | 12.92 | 15.93 | - | Upgrade
|
| Gross Profit | 20.66 | -7.01 | -15.92 | -3.89 | -3.93 | - | Upgrade
|
| Selling, General & Admin | 36.18 | 58.02 | 47.31 | 17.41 | 26.98 | 24.51 | Upgrade
|
| Research & Development | - | - | - | - | - | 15.67 | Upgrade
|
| Operating Expenses | 36.18 | 58.02 | 47.31 | 17.41 | 26.98 | 40.18 | Upgrade
|
| Operating Income | -15.52 | -65.04 | -63.22 | -21.3 | -30.91 | -40.18 | Upgrade
|
| Interest Expense | -8.78 | -9.41 | -3.96 | -2.17 | -4.3 | -3.03 | Upgrade
|
| Interest & Investment Income | 0.93 | 1.42 | 2.74 | 0.48 | 0.12 | 0.52 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.76 | -2.67 | -0.01 | -0.06 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -25.13 | -75.7 | -64.46 | -23.05 | -35.08 | -42.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.08 | -0.08 | -2.54 | - | - | - | Upgrade
|
| Legal Settlements | -0.8 | -0.8 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -1.44 | - | - | Upgrade
|
| Pretax Income | -26.01 | -76.58 | -67 | -24.49 | -35.08 | -42.69 | Upgrade
|
| Earnings From Continuing Operations | - | -76.58 | -67 | -24.49 | -35.08 | -42.69 | Upgrade
|
| Net Income | -26.01 | -76.58 | -67 | -24.49 | -35.08 | -42.69 | Upgrade
|
| Net Income to Common | -26.01 | -76.58 | -67 | -24.49 | -35.08 | -42.69 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 5 | 5 | 3 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 5 | 5 | 3 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | 89.19% | 14.26% | 32.72% | 26.32% | 8.20% | 0.39% | Upgrade
|
| EPS (Basic) | -2.96 | -14.78 | -14.78 | -7.17 | -12.97 | -17.08 | Upgrade
|
| EPS (Diluted) | -2.96 | -14.78 | -14.78 | -7.17 | -13.00 | -17.08 | Upgrade
|
| Free Cash Flow | -29.1 | -60.95 | -38.94 | -18.95 | -28.47 | -31.68 | Upgrade
|
| Free Cash Flow Per Share | -3.31 | -11.77 | -8.59 | -5.55 | -10.53 | -12.67 | Upgrade
|
| Gross Margin | 67.02% | -92.70% | - | -43.08% | -32.74% | - | Upgrade
|
| Operating Margin | -50.34% | -859.58% | -1233.84% | -235.78% | -257.57% | - | Upgrade
|
| Profit Margin | -84.38% | -1012.15% | -1307.47% | -271.11% | -292.33% | - | Upgrade
|
| Free Cash Flow Margin | -94.39% | -805.63% | -759.93% | -209.83% | -237.21% | - | Upgrade
|
| EBITDA | -14.96 | -64.08 | -62.67 | -20.84 | -30.66 | -40.14 | Upgrade
|
| EBITDA Margin | -48.52% | - | - | -230.76% | -255.53% | - | Upgrade
|
| D&A For EBITDA | 0.56 | 0.96 | 0.55 | 0.45 | 0.24 | 0.04 | Upgrade
|
| EBIT | -15.52 | -65.04 | -63.22 | -21.3 | -30.91 | -40.18 | Upgrade
|
| EBIT Margin | -50.34% | - | - | -235.78% | -257.57% | - | Upgrade
|
| Revenue as Reported | 30.83 | 7.57 | 5.12 | 9.03 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.